Tdspharm Co., Ltd. (KOSDAQ:464280)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,010.00
+160.00 (2.74%)
Aug 12, 2026, 3:30 PM KST

Tdspharm Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
30,41127,62127,51930,04925,58819,820
Revenue Growth
19.57%0.37%-8.42%17.43%29.11%9.97%
Gross Profit
8,5877,4897,7017,9106,1343,956
Operating Income
4,9203,7653,7305,0163,7812,314
Net Income
5,0554,2753,7184,6883,4562,063
Earnings Per Share
956.71808.27803.001101.00811.0022325.01
EPS Growth
42.92%0.66%-27.07%35.76%-96.37%65.21%

Revenue by Segment

Fiscal YearFY 2024FY 2023FY 2022FY 2021
Period EndingDec '24 Dec '23 Dec '22 Dec '21
Cataplasma
20,716---
Plasta
4,453---
Excluding Solid Content
2,349---
Cataplasma - All-in-One
-17,07013,5489,021
Cataplasma - Detachable
-5,0126,4275,651
Prescription Drugs
-2,9792,1622,289
Plasta - Menstruum
-2,7261,4351,615
Plasta - Hot Melt
-2,2631,401942

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
28,29520,21330,70415,1369,9378,122
Total Debt
13,9027,7126,9267,1456,9517,140
Net Cash (Debt)
14,39412,50123,7787,9912,986982.27
Net Cash Growth
-34.12%-47.43%197.58%167.60%203.99%249.25%
Net Cash Per Share
2724.372363.855135.781876.65700.7910630.51

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
4,9453,7803,9293,2942,9423,680
Capital Expenditures
-13,243-12,884-715.7-213.82-625.42-200.89
Free Cash Flow
-8,298-9,1043,2133,0802,3173,479
Free Cash Flow Growth
--4.34%32.92%-33.40%75.45%

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
28.24%27.12%27.98%26.32%23.97%19.96%
Operating Margin
16.18%13.63%13.55%16.69%14.77%11.68%
Pretax Margin
19.77%18.00%15.30%18.27%15.03%12.20%
Profit Margin
16.62%15.48%13.51%15.60%13.51%10.41%
FCF Margin
-27.29%-32.96%11.68%10.25%9.05%17.55%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
6.2812.7419.69---
P/FCF Ratio
--22.79---
PS Ratio
1.091.972.66---